IDH1-dependent m6A methylation defines transcriptomic heterogeneity in glioma

Area of Science:

• Molecular Biology
• Oncology
• Genomics

Background:

• Gliomas exhibit diverse clinical behaviors linked to IDH1 mutation status.
• Epigenetic alterations are known in gliomas, but RNA modifications like N6-methyladenosine (m6A) are less understood.
• m6A is a crucial epitranscriptomic mark influencing RNA fate.

Purpose of the Study:

• To generate the first isoform-resolved m6A maps in patient-derived gliomas.
• To investigate subtype-specific differences in m6A profiles between IDH1-mutant and wild-type gliomas.
• To explore the functional impact of m6A alterations on gene expression and clinical outcomes.

Main Methods:

• Direct RNA nanopore sequencing of patient-derived gliomas.
• Analysis of m6A methylation patterns, RNA modification enzymes, and RNA-binding proteins.
• Isoform-level and gene-level expression and prognostic association analyses.

Main Results:

• IDH1-mutant gliomas showed globally elevated m6A methylation with increased methyltransferases (METTL3, METTL14) and YTHDF3.
• Wild-type glioblastomas displayed enhanced expression of m6A erasers (ALKBH5, FTO) and YTHDF2.
• Subtype-specific m6A profiles influenced transcript stability, isoform usage, and gene expression, with isoform-level parameters showing stronger prognostic value.

Conclusions:

• m6A RNA modification is a critical, subtype-specific regulatory layer in glioma.
• Distinct m6A architectures in IDH1-mutant versus wild-type gliomas have significant clinical implications.
• Targeting m6A pathways presents potential therapeutic strategies for glioma treatment.